axumin
blue earth diagnostics ireland ltd - fluciclovine (18f) - prostatic neoplasms; radionuclide imaging - radiofármaco de diagnóstico - este medicamento é apenas para uso diagnóstico. axumin é indicado para tomografia por emissão de pósitrons (pet) de imagem para detectar a recorrência de câncer de próstata em homens adultos com suspeita de recorrência com base no sangue elevados antígeno específico da próstata (psa) após tratamento curativo primário.
nubeqa
bayer ag - darolutamide - prostática benigna neoplasias, a castração-resistente - terapia endócrina - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
cabazitaxel accord
accord healthcare s.l.u. - cabazitaxel - prostática benigna neoplasias, a castração-resistente - agentes antineoplásicos - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostática benigna neoplasias, a castração-resistente - rádiofarmacêutica terapêutica - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostática benigna neoplasias, a castração-resistente - agentes antineoplásicos - treatment of adult patients with prostate cancer.
vectormune fp ilt + ae
ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - frango - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.
vectormune fp ilt
ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - frango - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.
xtandi
astellas pharma europe b.v. - enzalutamida - neoplasias prostáticas - terapia endócrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
firmagon
ferring pharmaceuticals a/s - degarelix - neoplasias prostáticas - terapia endócrina - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
jevtana
sanofi winthrop industrie - cabazitaxel - neoplasias prostáticas - agentes antineoplásicos - jevtana em combinação com prednisona ou prednisolona é indicado para o tratamento de pacientes com câncer de próstata metastático hormônio-refratário previamente tratado com um regime contendo docetaxel.